Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Brice Chanez

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4688-8765; OpenAlex author ID A5033680248. Sources: OpenAlex.

Their work

Papers
17 (first author 3, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
75
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 2 papers · 2023: 2 papers · 2024: 1 paper · 2025: 3 papers · 2026: 8 papers

Papers 17

  1. Optimizing first-line NALIRIFOX and exploring the role of the microbiota in second-line pancreatic cancer treatment: the PRODIGE 105-GERCOR 116 PANORAMIX trial. Co-author DOI 10.1016/j.dld.2026.10.006↗
  2. Stage-resolved gene drivers of pancreatic ductal adenocarcinoma progression and therapeutic vulnerabilities. First author DOI 10.1016/j.isci.2026.115164↗
  3. Pathway-driven therapeutic stratification in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2026.102920↗
  4. Single-cell transcriptomic profiling of patient-derived pancreatic ductal adenocarcinoma primary cell cultures. Co-author DOI 10.1038/s41597-026-07380-3↗
  5. A comprehensive proteomic dataset of secretomes from primary pancreatic cancer cell cultures. Co-author DOI 10.1038/s41597-026-07902-z↗
  6. Factors Associated With Toxicity of FOLFIRINOX in Elderly Patients With Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1200/op-25-00358↗
  7. Co-translational O-glycosylation driven by GALNTs spatial reprogramming fosters pancreatic cancer growth Co-author DOI 10.64898/2026.09.04.749345↗
  8. Transcriptomic FOLFIRINOX sensitivity signatures stratify overall survival and reveal directional reclassification after neoadjuvant FOLFIRINOX in borderline r… Last author DOI 10.64898/2026.09.07.749857↗
  9. Toward Precision Chemotherapy for Pancreatic Cancer Guided by Transcriptomic Signatures. Co-author DOI 10.1002/ueg2.70124↗
  10. Medical management of pancreatic cancer: from personalization to broadening treatment strategies. Co-author DOI 10.1016/j.ctrv.2025.102973↗
  11. A Common CTRB misfolding variant associated with pancreatic cancer risk causes ER stress and inflammation in mice. Co-author DOI 10.1136/gutjnl-2024-333406↗
  12. Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.annonc.2024.06.010↗
  13. A Transcriptomic-Based Tool to Predict Gemcitabine Sensitivity in Advanced Pancreatic Adenocarcinoma. First author DOI 10.1053/j.gastro.2022.11.035↗
  14. Management and outcomes of brain metastases from pancreatic adenocarcinoma: a pooled analysis and literature review. Last author DOI 10.3389/fonc.2023.1326676↗
  15. Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity. Co-author DOI 10.1002/cac2.12365↗
  16. Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic c… Co-author DOI 10.1016/j.tranon.2021.101315↗
  17. Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma. First author DOI 10.1097/md.0000000000006544↗

Closest collaborators

The 25 strongest of 75 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nelson Dusetti · 12 shared papers, 2022–2026 · strength 2.60
  2. Juan Iovanna · 10 shared papers, 2022–2026 · strength 2.09
  3. Nicolas Alejandro Fraunhoffer · 9 shared papers, 2022–2026 · strength 2.03
  4. Julie Roques · 5 shared papers, 2022–2026 · strength 1.12
  5. Jonathan Garnier · 4 shared papers, 2023–2026 · strength 0.87
  6. Emmanuel Mitry · 5 shared papers, 2022–2026 · strength 0.85
  7. Cindy Neuzillet · 3 shared papers, 2025–2026 · strength 0.77
  8. Jean‐Baptiste Bachet · 4 shared papers, 2022–2026 · strength 0.73
  9. Pascal R. Hammel · 4 shared papers, 2022–2026 · strength 0.69
  10. Rémy Nicolle · 4 shared papers, 2022–2025 · strength 0.63
  11. Eduardo Chuluyán · 3 shared papers, 2022–2026 · strength 0.58
  12. Philippe Soubeyran · 2 shared papers, 2026 · strength 0.58
  13. Odile Gayet · 3 shared papers, 2022–2026 · strength 0.55
  14. Matthieu Delaye · 2 shared papers, 2025–2026 · strength 0.55
  15. Jerome F. Cros · 3 shared papers, 2022–2025 · strength 0.49
  16. Nicolas Williet · 2 shared papers, 2025–2026 · strength 0.46
  17. Oscar Mazza · 2 shared papers, 2026 · strength 0.42
  18. María Eugenia Pasqualini · 2 shared papers, 2026 · strength 0.42
  19. María Noé Garcia · 2 shared papers, 2026 · strength 0.42
  20. Agustín Yaneff · 2 shared papers, 2026 · strength 0.42
  21. Daniela Laura Papademetrio · 2 shared papers, 2026 · strength 0.42
  22. Daniel Grasso · 2 shared papers, 2026 · strength 0.42
  23. Flora Poizat · 2 shared papers, 2023–2026 · strength 0.41
  24. Olivier Bouché · 2 shared papers, 2024–2026 · strength 0.40
  25. Anthony Turpin · 2 shared papers, 2024–2025 · strength 0.37

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.